A Clinical Trial of TAA06 Injection in Advanced Solid Tumors

NCT ID: NCT05190185

Last Updated: 2022-01-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2023-12-01

Brief Summary

B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn't express on normal tissues. Therefore, B7-H3 is an ideal target for chimeric antigen receptor (CAR) T cells therapy. TAA06 injection is a CAR T injection targeting B7-H3. This is a phase I clinical study with the primary objective of evaluating the safety and tolerability of TAA06 injection in subjects with TAA06-positive advanced solid tumors. The secondary objectives are as follows: to evaluate the distribution, proliferation and persistence of B7-H3-targeted CAR T cells after injection of TAA06 in subjects; to preliminarily evaluate the efficacy of TAA06 injection in subjects with TAA06-positive advanced solid tumor.

Conditions

Malignant Melanoma, Lung Cancer, or Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TAA06 injection

T cell injection targeting B7-H3 chimeric antigen receptor

Group Type: EXPERIMENTAL

TAA06 injection

Intervention Type: BIOLOGICAL

The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.

Interventions

TAA06 injection

The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• (1) Aged 18 to 70 years old (inclusive), male or female;
• (2) Expected survival time ≥ 12 weeks;
• (3) ECOG performance status of 0-1;
• (4) It is clearly diagnosed by pathology to be any of the following tumor types: malignant melanoma, lung cancer or colorectal cancer, and the positive rate of TAA06 expression in tumor tissues is ≥1% after immunohistochemical detection;
• (5) Subjects whose standard treatment methods are ineffective (eg: relapse after surgery, disease progress after treatment with chemotherapy, radiotherapy or targeted drugs);
• (6) According to the curative effect evaluation standard for solid tumors (RECIST 1.1), at least one measurable lesion (the longest diameter of the solid lesion ≥ 10mm, or the short diameter of the lymph node lesion ≥ 15mm);
• (7) The main organ function is normal (white blood cell count ≥3×109/L, neutrophil count ≥1.5×109/L, hemoglobin ≥8.5g/dL, platelet count ≥80×109/L, lymphocyte count at 1×109/L (inclusive) ~ 4×109/L (inclusive));
• (8) Liver and kidney function, heart and lung function meet the following criteria:

1. Urea (Urea) and serum creatinine≤1.5×ULN;

2. Left ventricular ejection fraction ≥50%;

3. Baseline blood oxygen saturation ≥ 94%;

4. Total bilirubin≤1.5×ULN; ALT and AST≤2.5×ULN;

• (9) The subjects or his legal representative can fully understand the significance and risks of this trial and has signed informed consents.

Exclusion Criteria

• (1) Subjects with a history of immunodeficiency or autoimmune diseases (including but not limited to rheumatoid joint disease, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes, etc.); with graft-versus-host disease (GVHD) , Or those who need to use immunosuppressive agents;
• (2) Subjects with other type of malignant tumors within 5 years prior to screening;
• (3) Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood hepatitis B virus (HBV) DNA titer detection not within the normal reference range; positive for hepatitis C virus (HCV) antibody and peripheral blood hepatitis C virus (HCV) RNA; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis test;
• (4) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ III), severe arrhythmia;
• (5) Unstable systemic diseases judged by the investigator: including but not limited to serious liver, kidney or metabolic diseases requiring drug treatment;
• (6) Within 7 days prior to screening, there are active or uncontrollable infections requiring systemic therapy (except for mild genitourinary infection and upper respiratory tract infection);
• (7) Pregnant or lactating women, and female subjects who plan to become pregnant within 1 year after cell infusion or male subjects whose partners plan to become pregnant within 1 year after cell infusion;
• (8) Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening;
• (9) Subjects who are receiving systemic steroid therapy within 7 days prior to screening or need long-term use of systemic steroid therapy during treatment as judged by the investigator (except for inhalation or topical use);
• (10) Subjects with more than a moderate amount of ascites, or after conservative medical treatment (such as diuresis, sodium restriction, excluding ascites drainage) for 2 weeks, the ascites still shows a progressive increase;
• (11) Conditions not eligible for cell preparation as judged by the investigator;
• (12) Other conditions considered unsuitable for enrollment by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hebei Medical University Fourth Hospital

OTHER

Sponsor Role: collaborator

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

PersonGen BioTherapeutics(Suzhou) Co., Ltd.

Suzhou, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Zhiyu Wang, Doctor

Role: CONTACT

drwangzhiyu@hebmu.edu.cn

+86-138 3119 5070

Facility Contacts

Huimin Meng, Doctor

Role: primary

huimin.meng@persongen.com.cn

+86-18015580390

Other Identifiers

PG-CART-TAA06-001

Identifier Type: -

Identifier Source: org_study_id